USPTO Examiner SAMALA JAGADISHWAR RAO - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18983625GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGINGDecember 2024June 2025Allow610NoNo
18905806FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONSOctober 2024April 2025Allow611YesNo
18745906COPPER-64 COMPOSITIONS AND FORMULATIONSJune 2024October 2024Allow400YesNo
18745896PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64June 2024March 2025Allow920YesNo
18646526MULTI-MODE IMAGING MARKERSApril 2024December 2024Allow700YesNo
18610095METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMAMarch 2024September 2024Allow610NoNo
18604397COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOFMarch 2024August 2024Allow510YesNo
18428591CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGINGJanuary 2024March 2025Allow1300NoNo
18511854STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOFNovember 2023February 2024Allow300YesNo
18499758METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXESNovember 2023August 2024Allow911YesNo
18238966PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2023March 2024Allow710NoNo
18238972PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2023October 2024Allow1430NoNo
18238951PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2023July 2024Allow1111YesNo
18448682PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPYAugust 2023September 2024Allow1300YesNo
18232013METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMAAugust 2023October 2023Allow200YesNo
18363369METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITYAugust 2023December 2024Allow1700YesNo
18213194PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64June 2023March 2024Allow910YesNo
18339195ENGINEERED RADIOACTIVE POLYMERIC MICROSPHERE, AND PREPARATION AND APPLICATION THEREOFJune 2023September 2023Allow300YesNo
18205751METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASESJune 2023April 2025Allow2210NoNo
18203326COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOFMay 2023February 2025Allow2101YesNo
18324420STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOFMay 2023September 2023Allow410NoNo
18303708PSMA-Targeting Ligands With Optimal Properties for Imaging and TherapyApril 2023June 2024Allow1420YesNo
18161395PSMA-Targeting Ligands With Optimal Properties for Imaging and TherapyJanuary 2023September 2024Allow2000YesNo
18156319ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2023August 2023Allow700YesNo
18150542Granzyme B Directed Imaging and TherapyJanuary 2023November 2024Allow2200NoNo
18063349LIQUID VEHICLE FOR ENTEROGRAPHY EXAMINATIONDecember 2022June 2025Allow3010YesNo
17993186PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64November 2022August 2023Allow910YesNo
18056856IMAGING METHODS USING DEUTERATED COMPOUNDSNovember 2022September 2024Allow2210NoNo
18051422PRISTINE GRAPHENE BASED BIOSENSOR FOR BIOMARKER DETECTION AND RELATED CORE PARTICLES, MATERIALS COMPOSITIONS METHODS AND SYSTEMSOctober 2022June 2025Allow3111YesNo
17976664STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOFOctober 2022April 2023Allow500YesNo
17969297METHOD OF PREVENTING THE DEVELOPMENT OF MELANOMAOctober 2022March 2023Allow500YesNo
17933234NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAMESeptember 2022March 2025Allow3010NoNo
17943754STRUCTURAL DESIGN OF A CRANIAL NERVE DEGENERATION CONTRAST AGENT PRECURSORSSeptember 2022June 2025Allow3300NoNo
17901072TRIARYL METHANE COMPOSITION, DYE COMPOSITION FOR OCULAR MEMBRANE DYEINGSeptember 2022March 2025Abandon3110NoNo
17894874PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64August 2022November 2022Allow200YesNo
17892769NOVEL PEPTIDE-BASED CANCER IMAGING AGENTSAugust 2022February 2025Abandon3010NoNo
17889655DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOFAugust 2022August 2024Allow2400YesNo
17884751METHODS OF IMAGING AND DELIVERING THERAPEUTIC AGENTSAugust 2022April 2025Abandon3301NoNo
17881895PROBES FOR IMAGING HUNTINGTIN PROTEINAugust 2022November 2024Allow2710NoNo
17794843NOVEL GADOLINIUM-BASED COMPOUND, METHOD FOR PRODUCING SAME, AND MRI CONTRAST AGENT CONTAINING SAMEJuly 2022May 2025Allow3400YesNo
17858859STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOFJuly 2022September 2022Allow200NoNo
17857990METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXESJuly 2022October 2023Allow1530YesNo
17810316Macrocyclic Chelators and Methods of Use ThereofJune 2022February 2025Allow3110YesNo
17786980ECO-FRIENDLY SMART PHOTOSENSITIZER AND PHOTO-STEM CELL THERAPY PRODUCT COMPRISING SAMEJune 2022March 2023Allow900YesNo
17803382Borylated amino acid compositions for use in boron neutron capture therapy and methods thereofJune 2022June 2024Allow2400YesNo
17750333DOTMP KIT FORMULATIONS FOR RADIOISOTOPESMay 2022December 2024Allow3110YesNo
17769986METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIOSISApril 2022August 2024Allow2821YesYes
17697426NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASESMarch 2022July 2023Abandon1611NoNo
17692289COMPOSITIONS AND METHODS FOR REMOVING BIO-SYNTHETIC NANO-PARTICLES FROM BODILY FLUIDSMarch 2022April 2023Abandon1321YesYes
17678782MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCERFebruary 2022November 2024Allow3301YesNo
17678803MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCERFebruary 2022June 2024Allow2700YesNo
17665202STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOFFebruary 2022July 2022Allow501YesNo
17590504ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOFFebruary 2022December 2022Allow1111YesNo
17553113FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPYDecember 2021April 2025Allow4020YesNo
17550731BIOORTHOGONAL COMPOSITIONSDecember 2021August 2024Allow3201YesNo
17518794SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOFNovember 2021December 2024Abandon3701NoNo
17451536CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGINGOctober 2021November 2023Allow2500YesNo
17450212TAU PET IMAGING LIGANDSOctober 2021February 2024Allow2810YesNo
17494367RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPYOctober 2021January 2022Allow300YesNo
17492260COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATUREOctober 2021February 2025Allow4120NoNo
17448463Half-Curcuminoids as Amyloid-Beta PET Imaging AgentsSeptember 2021August 2024Allow3510YesNo
17480924Half-Curcuminoids as Amyloid-Beta PET Imaging AgentsSeptember 2021February 2024Allow2910YesNo
17473820MULTI-MODE IMAGING MARKERSSeptember 2021January 2024Allow2800YesNo
17466443PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64September 2021August 2022Allow1221YesNo
17403429Methods of Imaging and Delivering Therapeutic AgentsAugust 2021December 2021Allow400YesNo
17392453METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASESAugust 2021January 2024Allow3010YesNo
17389674NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USESJuly 2021April 2024Allow3210YesNo
17443863ASCORBATE FORMULATIONS AND METHODS OF USE AS CONTRAST AGENTSJuly 2021January 2025Allow4220YesNo
17379011MULTINUCLEAR COMPLEXES AND THEIR PREPARATIONJuly 2021April 2023Allow2131YesNo
17352647METHOD FOR PREPARATION OF HIGHLY POLARIZED NUCLEAR SPINS CONTAINING SAMPLES AND USES THEREOF FOR NMR AND MRIJune 2021February 2025Abandon4420NoNo
17350304GEL FORMULATIONS FOR LOCAL DRUG RELEASEJune 2021October 2024Allow4011YesNo
17331750CXCR7 ANTAGONISTSMay 2021July 2023Allow2600YesNo
17295609COMPOSITION OF RADIOACTIVE AND NON-RADIOACTIVE MICROPARTICLESMay 2021February 2024Allow3232YesNo
17292455METHOD FOR PREPARING ALBUMIN NANOPARTICLES BASED ON FREE RADICAL OXIDATIONMay 2021March 2022Allow1011YesNo
17292479CHELATING AAZTA CONJUGATES AND COMPLEXES THEREOFMay 2021May 2023Allow2410YesNo
17314538CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONEMay 2021February 2022Allow1011YesNo
17307857PHARMACEUTICAL PREPARATIONMay 2021April 2024Abandon3501NoNo
17245872FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPYApril 2021June 2023Allow2500NoNo
17237850PSMA-BINDING AGENTS AND USES THEREOFApril 2021April 2024Allow3610YesNo
17218907HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGINGMarch 2021June 2023Allow2600YesNo
17212995BACTERIALLY DERIVED, INTACT MINICELLS FOR DELIVERY OF THERAPEUTIC AGENTS TO BRAIN TUMORSMarch 2021December 2023Allow3310YesNo
17204561Methods of Imaging and Delivering Therapeutic AgentsMarch 2021May 2021Allow200YesNo
17198574METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITYMarch 2021October 2022Allow2030YesYes
17195895SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYLMarch 2021August 2023Allow2900YesNo
17189131COATED UP-CONVERSION NANOPARTICLESMarch 2021October 2024Abandon4320NoNo
17165130COMPOSITION FOR INCREASING PERMEABILITY OF BLOOD-BRAIN BARRIER COMPRISING NITRIC OXIDE DONOR AND USE THEREOFFebruary 2021November 2023Abandon3320NoNo
1716285617110558January 2021May 2021Allow410YesNo
17154926METHODS AND KITS FOR PREPARING RADIONUCLIDE COMPLEXESJanuary 2021March 2024Allow3710YesNo
17143280USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCERJanuary 2021June 2023Allow3000YesNo
17134709RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOFDecember 2020September 2024Allow4420YesNo
17131475BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOFDecember 2020November 2024Abandon4721NoNo
17114698OXYGEN SENSORSDecember 2020March 2024Allow3920NoNo
17110558LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCERDecember 2020November 2023Allow3510NoNo
17110133BIOMARKERS FOR NANOPARTICLE COMPOSITIONSDecember 2020March 2023Abandon2831YesNo
17099511Radiotracer Derivatives Of Trimethoprim For Diagnostic ImagingNovember 2020August 2023Abandon3310NoNo
17093252ISOTOPE PREPARATION METHODNovember 2020April 2025Abandon5321NoNo
17079724PLASTIC CONTAINERSOctober 2020December 2022Allow2600YesNo
17047638TARGETED NANOPARTICLES FOR DIAGNOSING, DETECTING AND TREATING CANCEROctober 2020January 2025Abandon5221NoNo
17032132Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy AgentsSeptember 2020September 2022Allow2410NoNo
17025277MICROPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF TELMISARTAN AND ACTINOMYCIN DSeptember 2020November 2023Allow3811YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAMALA, JAGADISHWAR RAO.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
8
(61.5%)
Examiner Reversed
5
(38.5%)
Reversal Percentile
58.9%
Higher than average

What This Means

With a 38.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
87
Allowed After Appeal Filing
20
(23.0%)
Not Allowed After Appeal Filing
67
(77.0%)
Filing Benefit Percentile
27.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SAMALA, JAGADISHWAR RAO - Prosecution Strategy Guide

Executive Summary

Examiner SAMALA, JAGADISHWAR RAO works in Art Unit 1618 and has examined 1,108 patent applications in our dataset. With an allowance rate of 71.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner SAMALA, JAGADISHWAR RAO's allowance rate of 71.6% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by SAMALA, JAGADISHWAR RAO receive 1.52 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SAMALA, JAGADISHWAR RAO is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +53.7% benefit to allowance rate for applications examined by SAMALA, JAGADISHWAR RAO. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.3% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 38.2% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 83.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.0% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 67.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 54.9% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.5% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.